How much do you know about the role of CAR T cells in multiple myeloma? Here's your chance to find out.
Autologous stem cell transplant has become safer over the years for patients with multiple myeloma and renal insufficiency.
CAR T cells are a more effective therapy if manufactured for patients with multiple myeloma prior to the onset of relapsed or refractory disease.
The combination use of Darzalex with bortezomib, thalidomide, and dexamethasone was approved for transplant-eligible patients with multiple myeloma.
A new study suggests there is a cost and efficiency benefit to pre-emptively administrating plerixafor during stem cell collection.
Patients with multiple myeloma whose disease progresses on BCMA-targeted therapy can possibly respond to a different BCMA-targeted therapy.
Researchers looked to see how a patient's monoclonal gammopathy of undetermined significance status affects their risk for multiple myeloma.
How much do you know about thrombotic microangiopathies in multiple myeloma? Here's your chance to find out.
Older adults with multiple myeloma are not receiving the recommended care which includes bone-modifying drugs, antiviral prophylaxis, and the influenza vaccine.
New data push back against previous thinking that an individual's risk of progression from MGUS to multiple myeloma was constant.